You walk into the chemist.
You hand over the prescription.
You pay full price for a branded tablet — because surely, branded means safe.
Except… this month, in 157 cases, it didn't.
India's drug regulator CDSCO just released its May 2026 report.
157 branded medicine samples. Failed quality testing.
And this isn't some obscure niche stuff.
These are the tablets sitting in your mom's pill box. Your dad's BP strip. Your own emergency drawer.
The everyday names that flunked:
Some had the wrong amount of active drug salt.
Some had a broken combination.
Translation: the patient swallows it… and the body gets almost nothing.
It's not just pills.
All failed. All of it.
And the names attached to some of these batches? Cipla. Sun Pharma. The giants. The household trust marks.
Look at 2026 so far:
That's over 900 substandard drug samples in five months. In the country that calls itself the pharmacy of the world — exporting medicines to 200+ countries.
About 30-40 crore Indians take some kind of medicine every single day.
A city family spends ₹12,400 a year on health. A village family, ₹10,500 — often money squeezed out of daily wages.
The share of people falling sick every fortnight has jumped from 7.5% to over 13%.
So people are getting sicker. Spending more. Trusting more.
And quietly, some of those trusted tablets are doing… nothing.
A failed quality test isn't a paperwork problem.
It's a diabetic whose sugar won't come down.
A heart patient whose BP keeps spiking.
A child whose fever just won't break.
India doesn't have a medicine access problem anymore.
It has a medicine trust problem.
And until that trust is rebuilt, every strip in every chemist's drawer carries a quiet, invisible question mark.
That's all for now!
